iPark Institute and KBIOHealth to Engage in Full-Scale Business Activities in South Korea through Collaboration -Mutual Exchanges and Joint Exhibitions to be Continued-.
Press Release
Jul 12, 2024
iPark Institute Co., Ltd.
iPark Institute and KBIOHealth to Engage in Full-Scale Business Activities in South Korea through Collaboration -Mutual Exchanges and Joint Exhibitions to be Continued-
The iPark Institute sent its first staff to KBIOHealth on June 25-27.
Both companies jointly exhibited at InterBiz in Jeju, South Korea, July 3-5.
Plans call for periodic mutual exchanges and joint events in the future.
iPark Institute Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture; CEO: Toshio Fujimoto; hereafter known as “iPark Institute”) started full-scale business activities in South Korea in late June through mutual exchanges and joint exhibitions with the Osong Medical Innovation Foundation, (KBIOHealth) (Headquarters: Cheongju City, Chungcheongbuk-do; Chairman & CEO: Cha Sang-Hoon; hereafter known as “KBIOHealth”).
iPark Institute and KBIOHealth signed a memorandum of understanding for mutual cooperation in the healthcare domain in January of this year and opened offices in each other’s facilities. iPark Institute and KBIOHealth conducted personnel dispatches and joint exhibitions in South Korea from the end of June to early July.
June 25-27
This was the first dispatch from iPark Institute.
Two iPark Institute employees visited the KBIOHealth facility in Osong to exchange information about each other’s organizations and discuss future initiatives.
July 3-5
In addition to visiting the KBIOHealth facilities in South Korea, two iPark Institute employees also participated in the 22nd InterBiz Bio-Partnering & Investment Forum 2024 in Jeju, where they met with approximately 30 South Korean companies.
In the future, a representative from KBIOHealth will stay at Shonan iPark for two weeks in late July, and online joint events are also planned.
Through face-to-face personal exchanges and business activities in Japan and South Korea locally, we aim to strengthen our collaboration and lead to the development of a Japan-South Korea life science ecosystem that leverages each country’s strengths.
Personnel dispatched to KBIOHealth
Joint Exhibition at InterBiz
About The 22nd InterBiz Bio-Partnering & Investment Forum 2024
The event aimed to increase the potential for commercialization of promising technologies through technology transfer, licensing, joint research, and attracting investment by inviting R&D professionals from industry and academia in South Korea and promoting partnerships. The event was held in Jeju, South Korea, from July 3 to 5 and was co-hosted by 16 South Korean organizations, including KBIOHealth.
About KBIOHealth (Osong Medical Innovation Foundation, South Korea)
The Osong Medical Innovation Foundation (KBIOHealth) is a government-led agency under the Ministry of Health and Welfare, established to foster the bio-health industry as a future national growth engine. It serves as an “R&D service platform” that aims to promote an advanced medical industry through the activation and dissemination of research in the fields of biopharmaceuticals and biotechnology-based medical devices and provides the services the government needs by filling in areas that tend to be lacking in the private sector.
In addition to supporting applied development research, the Foundation also provides consulting on research directions for commercial development. Recognizing that even projects with the potential for successful commercialization often face obstacles in the early stages or encounter difficulties later on, the Foundation, as a national infrastructure, corrects these directions and guides them through the commercialization phase.
Built in November 2013, the center has four core facilities: the Center for New Drug Development, the Center for Advanced Medical Device Development, the Center for Non-clinical Evaluation, and the Center for Biopharmaceutical Manufacturing. Each has advanced facilities and equipment to support the development of biopharmaceuticals and BT-based medical devices.
About iPark Institute Co., Ltd.
iPark Institute Co., Ltd. was established in 2023 with Industrial & Infrastructure Fund Investment Corporation (IIF), Takeda Pharmaceutical Company Limited (Takeda), and Mitsubishi Corporation as major shareholders. It took over the management of Shonan Health Innovation Park (Fujisawa City, Kanagawa Prefecture) in 2023, which Takeda has been responsible for since 2018. For more information about our company, please click here.
About Shonan Health Innovation Park (Shonan iPark)
Shonan iPark is Japan’s first pharmaceutical-initiated science park, created by Takeda Pharmaceutical Company Limited in April 2018 by opening its own research laboratories to the outside world. Currently operated by iPark Institute Co., Ltd. independent of Takeda Pharmaceutical Company Limited, the park aims to become a place where industry, government, and academia from a wide range of industries and sizes can come together to accelerate health innovation. Currently, the ecosystem is comprised of not only pharmaceutical companies, but also companies and organizations in nextgeneration medicine, cellular agriculture, AI, and government, with approximately 180 companies and more than 2,500 people (as of July 2024).
Click here for homepage
For the latest information on tenants and member companies at Shonan iPark, click here.
Official social links: YouTube / Facebook / X (former Twitter) / LinkedIn
For inquiries regarding this matter, please contact:
iPark Institute Co., Ltd., Communications
Attn: Takizawa, Hibino
Mail: iPi.PR@shonan-ipark.com